What is Experic?
Experic operates as a crucial partner in the pharmaceutical industry, offering end-to-end services that span the entire product lifecycle. The company specializes in supporting development and manufacturing across various dosing and packaging formats, including tablets, pellets, capsules, and low-dose dry powder inhalation. Operating from a state-of-the-art, Class A cGMP facility, Experic is equipped to manage global delivery of high-quality pharmaceutical products, even for expedited projects, underscoring its commitment to unparalleled knowledge, expertise, and customer service in the competitive CDMO landscape.
How much funding has Experic raised?
Experic has raised a total of $14.2M across 2 funding rounds:
Debt
$150K
Series B
$14M
Debt (2020): $150K with participation from PPP
Series B (2022): $14M led by East Seattle Partners and Harro Höfliger
Key Investors in Experic
East Seattle Partners
East Seattle Partners is a multi-asset investment firm specializing in growth equity and real estate investments, founded by Alan Frazier. The firm focuses on investing in growth companies that aim to redefine business categories and address market challenges, as well as in the renovation of historically significant real estate properties. With a commitment to creating lasting impact, East Seattle Partners provides capital, resources, and expertise to help companies become market leaders while enhancing community value. Their experienced team emphasizes strategic thinking and partnership in every investment endeavor.
Harro Höfliger
Harro Höfliger is a key player in the pharmaceutical manufacturing equipment sector, known for its innovative solutions in processing and packaging technologies. Their involvement suggests a strategic alignment with Experic's manufacturing and development capabilities, potentially indicating a partnership focused on enhancing production efficiency and technological advancement within the pharmaceutical supply chain.
PPP
Public-Private Partnership
What's next for Experic?
With the recent enterprise-level investment, Experic is poised for accelerated growth and expansion of its service offerings. The company's focus on quality, compliance, and efficient global delivery suggests a strategic direction towards scaling its manufacturing capabilities and potentially broadening its technological expertise in specialized drug delivery systems. This capital will likely fuel advancements in its state-of-the-art facility and bolster its capacity to handle complex projects, reinforcing its position as a key player in the pharmaceutical supply chain and supporting the development of novel therapeutics.
See full Experic company page
